This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Anthera Pharmaceuticals, Inc.
Drug Names(s): liprotamase, Trizytek, ALTU-135, TheraCLEC, porcine-free enzymes, Solpura
Description: Trizytek (ALTU-135) consists of three pancreatic enzymes for the treatment of malabsorption that results from pancreatic insufficiency. This condition is seen in patients with cystic fibrosis, chronic pancreatitis, pancreatic cancer, and HIV/AIDS. The enzymes digest protein (protease), fat (lipase), and starches (amylase). ALTU-135 uses a proprietary protein crystallization and cross-linking technology to create a stable protein product.
CFFT and Altus
In March 2001, the Cystic Fibrosis Foundation announced that its subsidiary, the Cystic Fibrosis Foundation Therapeutics (CFFT), and Altus Biologics have formed an alliance to expedite the development of TheraCLEC-Total. CFFT will provide Altus with up to $25 million in grant funding as well as access to its Therapeutics Development Network.
In January 2009, Altus Pharmaceuticals announced a strategic realignment of product development priorities to focus on the advancement of ALTU-238 as a once-per-week treatment for adult and pediatric patients with growth hormone deficiency. To conserve capital resources, Altus will discontinue its Trizytek program activities. This discontinuation will result in the transfer of certain Trizytek intellectual property rights and regulatory filings to CFFT in accordance with Altus' 2001 agreement with CFFT.
Altus expects that discontinuation of the Trizytek program will terminate the Company's exclusive sublicense to...See full deal structure in Biomedtracker
Partners: Cystic Fibrosis Foundation Therapeutics, Inc.
Additional information available to subscribers only: